# Study of Pembrolizumab in Locally Advanced Esophageal Adenocarcinoma

> **NCT02998268** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Weill Medical College of Cornell University** · enrollment: 42 (actual)

## Conditions studied

- Esophageal Adenocarcinoma

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Taxol
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT02998268
- **Lead sponsor:** Weill Medical College of Cornell University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-03-07
- **Primary completion:** 2021-02-10
- **Final completion:** 2026-03
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2026-03-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02998268

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02998268, "Study of Pembrolizumab in Locally Advanced Esophageal Adenocarcinoma". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT02998268. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*